Disparities in OUD treatment: Buprenorphine vs. naltrexone
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
Amgen’s new retrospective study, VESALIUS-REAL, examines how lipid-lowering therapy (LLT) is being...
Antiretroviral therapy (ART) has transformed outcomes for people living with HIV, especially those...
Government health agencies are increasingly turning to real-world data (RWD) for public health...
A new peer-reviewed study from the Centers for Disease Control and Prevention (CDC) highlights the...
Background While the COVID-19 pandemic is behind us, the virus remains a concern that needs to be...
The COVID-19 pandemic illustrated how vital government communications can be for effective public...
Medicaid provides much-needed healthcare coverage to over 70 million people, almost half of whom...
While the CDC is considered the nation’s leading authority on infectious diseases, it is also...
Our series on how Privacy Preserving Record Linkage (PPRL) technology can help government agencies...
Why real-world data matters in epilepsy research Epilepsy affects millions of adults in the United States, and many patients live with intractable seizures that are difficult to control. As new antiseizure medications (ASMs) are approved, researchers...